Tricida to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 11:50 am PT / 2:50 pm ET. CEO Gerrit Klaerner will discuss the company's overview and key initiatives. Investors can access a live webcast on the Tricida website, with an archived version available for 90 days post-presentation. Tricida focuses on developing veverimer (TRC101), an investigational drug for treating metabolic acidosis in chronic kidney disease (CKD) patients, which affects approximately three million individuals in the U.S.

News Market Reaction – TCDA

+4.21%

+4.21% Session move

In the trading session that priced this news, TCDA gained 4.21%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 11:50 am PT / 2:50 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives.

A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. There are no FDA-approved treatments for chronic metabolic acidosis, a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon, IRC
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

FAQ

When will Tricida present at the J.P. Morgan Healthcare Conference?

Tricida will present on January 13, 2021, at 11:50 am PT / 2:50 pm ET.

Who will represent Tricida at the conference?

CEO Gerrit Klaerner will represent Tricida at the conference.

Where can I watch Tricida's presentation?

You can watch the live webcast of Tricida's presentation on their official website.

What is Tricida's investigational drug candidate?

Tricida's investigational drug candidate is veverimer (TRC101), designed to treat metabolic acidosis in CKD patients.

How many patients with CKD could potentially benefit from Tricida's drug?

Approximately three million patients with chronic kidney disease in the U.S. could benefit from Tricida's drug.